Relay Therapeutics (NASDAQ:RLAY) Shares Down 6.7% – Here’s What Happened

Relay Therapeutics, Inc. (NASDAQ:RLAY) shares dropped 6.7% during mid-day trading on Wednesday . The stock traded as low as $7.94 and last traded at $7.93. Approximately 348,337 shares changed hands during trading, a decline of 84% from the average daily volume of 2,208,316 shares. The stock had previously closed at $8.50.

Trending Headlines about Relay Therapeutics

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: Technical/quote signal — MarketBeat notes an intraday uptick and that shares are trading above the 200‑day moving average, a constructive technical sign that can attract momentum buyers. MarketBeat RLAY quote
• Positive Sentiment: Analyst support — Recent upgrades (Oppenheimer to Outperform; Wells Fargo to Overweight) and a consensus “Moderate Buy” rating give fundamental/flow support that can limit downside from short‑term selling. Analyst commentary
• Neutral Sentiment: Insiders still hold large stakes — filings show executives retain hundreds of thousands of shares after the sales, so these transactions reduce ownership modestly but are not a change of control signal. (See SEC filings for details.) SEC ownership filing
• Negative Sentiment: CFO selling — CFO Thomas Catinazzo sold 13,820 shares on Jan. 27 (~$105k at ~$7.62) and an additional 1,695 shares on Jan. 28 (~$14.3k at ~$8.45). Multi‑day sales by the CFO amplify concerns and can sap near‑term sentiment. Catinazzo filings
• Negative Sentiment: Other insider sales clustered over Jan. 27–28 — Director/executive Peter Rahmer sold ~11.7k and 1,354 shares across two days; Donald Bergstrom sold ~18.9k and 2,686 shares. The concentration and timing of sales by multiple insiders increase short‑term selling pressure. Rahmer filings Bergstrom filings
• Negative Sentiment: Market commentary citing a notable intraday decline (~5.2%) amplifies negative sentiment and may trigger momentum selling even if fundamentals are unchanged. Why RLAY is down 5.18%

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on RLAY shares. Weiss Ratings restated a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Friday, January 9th. Wells Fargo & Company raised Relay Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $6.00 to $13.00 in a research note on Friday, December 12th. Finally, Oppenheimer raised shares of Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 price objective for the company in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.57.

Relay Therapeutics Stock Down 0.6%

The firm has a fifty day moving average of $7.96 and a 200 day moving average of $5.95.

Relay Therapeutics (NASDAQ:RLAY) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). As a group, equities analysts expect that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Insider Activity

In related news, CEO Sanjiv Patel sold 62,073 shares of Relay Therapeutics stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $7.00, for a total value of $434,511.00. Following the sale, the chief executive officer directly owned 703,215 shares in the company, valued at $4,922,505. The trade was a 8.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Donald A. Bergstrom sold 18,895 shares of the business’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $7.62, for a total value of $143,979.90. Following the sale, the insider directly owned 422,733 shares in the company, valued at $3,221,225.46. This trade represents a 4.28% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 155,375 shares of company stock valued at $1,158,866. 4.87% of the stock is owned by insiders.

Hedge Funds Weigh In On Relay Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Torren Management LLC acquired a new position in Relay Therapeutics during the 4th quarter worth approximately $30,000. FNY Investment Advisers LLC increased its position in shares of Relay Therapeutics by 100.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock worth $34,000 after purchasing an additional 5,000 shares during the last quarter. Quinn Opportunity Partners LLC acquired a new stake in Relay Therapeutics during the second quarter valued at approximately $35,000. May Hill Capital LLC bought a new position in Relay Therapeutics during the second quarter worth $38,000. Finally, Focus Partners Advisor Solutions LLC bought a new stake in shares of Relay Therapeutics during the 2nd quarter valued at about $39,000. 96.98% of the stock is owned by institutional investors and hedge funds.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.